INY-03-041 (trihydrochloride)
INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib conjugated to Lenalidomide (HY-A0003). INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively[1].
Product Specifications
UNSPSC
12352005
Target
Akt; PROTACs
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/iny-03-041-trihydrochloride.html
Purity
99.78
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C(N(CC1=C2C=CC=C1CCCCCCCCCCNC[C@H](C3=CC=C(Cl)C=C3)C(N4CCN(C5=C([C@H](C)C[C@H]6O)C6=NC=N5)CC4)=O)C2=O)CC7)NC7=O.Cl.Cl.Cl
Molecular Formula
C44H59Cl4N7O5
Molecular Weight
907.80
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Akt1; Akt2; Akt3; Cereblon
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
RSK4 (RPS6KA6) (NM_014496) Human Over-expression Lysate
Phaseolus Vulgaris Leucoagglutinin (PHA-L), CF®640R Conjugate
TIMP1 (Colorectal Cancer Biomarker / Marker of Lymph Node Metastasis) (rTIMP1/1710), 0.2mg/mL
